Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

WEIGHT-LOSS drugs can be a silver bullet for some trying to shed the pounds after years of failure with fad diets and exercise routines. But dodgy vendors selling potentially deadly fake jabs ...

It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company’s share price has tumbled some 60% over ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

European shares posted their biggest weekly gain in twelve weeks on Friday, as banking stocks continued to drive the ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...

Shares rose for a second day, in a rally sparked by rival Eli Lilly (LLY) reporting less-than-stellar trial results for an ...